Oddity Tech Ltd. (ODD)
| Market Cap | 793.80M -65.4% |
| Revenue (ttm) | 676.16M -13.4% |
| Net Income | 8.61M -92.2% |
| EPS | 0.15 -91.5% |
| Shares Out | 46.12M |
| PE Ratio | 113.33 |
| Forward PE | 17.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,327 |
| Open | 16.61 |
| Previous Close | 16.73 |
| Day's Range | 16.60 - 17.63 |
| 52-Week Range | 9.25 - 46.45 |
| Beta | 2.14 |
| Analysts | Hold |
| Price Target | 16.94 (-1.57%) |
| Earnings Date | Nov 11, 2026 |
About ODD
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States, Israel, and internationally. It serves consumers through its platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty, wellness, and technology products. The company provides a portfolio of products, including face and complexion, eye, brow and lip products, makeup tools, bodycare, medical grade presc... [Read more]
Financial Performance
In 2025, Oddity Tech's revenue was $809.84 million, an increase of 25.16% compared to the previous year's $647.04 million. Earnings were $110.75 million, an increase of 9.12%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ODD stock is "Hold." The 12-month stock price target is $16.94, which is a decrease of -1.57% from the latest price.
News
Oddity price target raised to $11 from $10 at BofA
BofA raised the firm’s price target on Oddity (ODD) to $11 from $10 and keeps an Underperform rating on the shares.
Oddity price target raised to $20 from $18 at Truist
Truist analyst Youssef Squali raised the firm’s price target on Oddity (ODD) to $20 from $18 and keeps a Hold rating on the shares. The company’s Q3 results and Q4…
Oddity price target raised to $10 from $9 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Oddity (ODD) to $10 from $9 and keeps a Sell rating on the shares. Oddity faces a prolonged growth and margin recovery…
Oddity price target raised to $15 from $12 at Barclays
Barclays raised the firm’s price target on Oddity (ODD) to $15 from $12 and keeps an Underweight rating on the shares. While Oddity announced the 2027 launch of prescription injectable…
Oddity Tech Earnings Call Transcript: Q3 2026
Q3 revenue and adjusted EBITDA beat guidance as SpoiledChild and METHODIQ grew, while IL MAKIAGE’s ad-account disruption persisted. FY 2026 guidance increased, and 2027 plans center on returning to growth through brand and peptide launches.
Oddity Tech Earnings release: Q3 2026
Oddity Tech released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
Oddity Tech Slides: Q3 2026
Oddity Tech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 11, 2026.
Oddity Tech Prepared remarks: Q3 2026
Oddity Tech filed a regulatory document on November 11, 2026 disclosing important business information.
Oddity reports Q3 adjusted EPS 37c, consensus 30c
Reports Q3 revenue $144.98M, consensus $140.47M. “We made further progress stabilizing our business and delivered strong results for SpoiledChild and METHODIQ,” said Oran Holtzman, ODDITY (ODD) co-fou...
ODDITY Tech Reports Third Quarter 2026 Results Ahead of Plan, Raises Full Year Net Revenue And Adjusted EBITDA Outlook
Third quarter net revenue of $145 million, down approximately 2% year-over-year Third quarter adjusted EBITDA of $22 million Third quarter net income of $11 million and third quarter adjusted net inco...
ODDITY to Announce Third Quarter 2026 Financial Results on November 11, 2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its third quarter 2026 financial results before the market open on Wednesday, November 1...
Oddity price target raised to $18.50 from $16.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Oddity (ODD) to $18.50 from $16.50 and keeps an Equal Weight rating on the shares.
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's pr...
Oddity resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Oddity (ODD) with a Neutral rating and $18 price target The firm is positive on Oddity’s “leading” scale, data-driven platform, and path toward a 2027 recovery.
Oddity price target raised to $18 from $16 at Truist
Truist raised the firm’s price target on Oddity (ODD) to $18 from $16 and keeps a Hold rating on the shares. Oddity’s Q2 results and Q3 outlook show sustained momentum…
Oddity price target raised to $10 from $8.50 at BofA
BofA raised the firm’s price target on Oddity (ODD) to $10 from $8.50 and keeps an Underperform rating on the shares. Q2 results were “better than feared” and show signs…
Oddity price target raised to $16.50 from $10 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian raised the firm’s price target on Oddity (ODD) to $16.50 from $10 and keeps an Equal Weight rating on the shares. Growth is recovering with…
Oddity price target raised to $9 from $8 at Goldman Sachs
Goldman Sachs analyst Bonnie Herzog raised the firm’s price target on Oddity (ODD) to $9 from $8 and keeps a Sell rating on the shares after its Q2 earnings beat.
Oddity price target raised to $18 from $16 at Jefferies
Jefferies raised the firm’s price target on Oddity (ODD) to $18 from $16 and keeps a Hold rating on the shares, calling the positive move in shares after the company…
Oddity Tech Earnings Call Transcript: Q2 2026
Net revenue declined 25% year-over-year due to IL MAKIAGE's ad algorithm issue, but SpoiledChild and METHODIQ showed strong growth and high repeat rates. The company expects sequential improvement, with Q3 revenue down ~5% and full-year revenue down ~19%.
Oddity Tech Earnings release: Q2 2026
Oddity Tech released its Q2 2026 earnings on September 9, 2026, summarizing the period's financial results.
Oddity Tech Prepared remarks: Q2 2026
Oddity Tech filed a regulatory document on September 9, 2026 disclosing important business information.
Oddity Tech Slides: Q2 2026
Oddity Tech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 9, 2026.
Oddity reports Q2 adjusted EPS 20c, consensus 12c
Reports Q2 revenue $180.52M, consensus $170.65M. “We made progress during the quarter, including strong results for both SpoiledChild and METHODIQ,” said Oran Holtzman, Oddity (ODD) co-founder and CEO...
ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter
Second quarter net revenue of $181 million, down approximately 25% year-over-year Second quarter adjusted EBITDA of $13 million Second quarter net income of $13 million and second quarter adjusted net...